Раны и раневые инфекции. Журнал имени проф. Б.М. Костючёнка

Расширенный поиск


Об авторе

В. В. Вельков


Список литературы

1. Moore L. J., Moore F. A., Todd S. R. et al. Sepsis in general surgery: the 2005–2007 national surgical quality improvement program perspective. Arch Surg 2010;145(7):695–700.

2. Kumar G., Kumar N., Taneja A. Nationwide trends of severe sepsis in the 21st century (2000–2007). Chest 2011;140(5):1223–31.

3. Lagu T., Rothberg M. B., Shieh M. S. et al. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 2012;40(3):754–61.

4. Namas R., Zamora R., Namas R. et al. Sepsis: Something old, something new, and a systems view. J Crit Care 2012;27(3):314. e1–11.

5. Mayr F. B., Yende S., Angus D. C. Epidemiology of severe sepsis. Virulence 2014;5(1):4–11.

6. Horeczko T., Green J. P., Panacek E. A. Epidemiology of the systemic inflammatory response syndrome (SIRS) in the Emergency Department. West J Emerg Med 2014;15(3):329–36.

7. Angus D. C., Linde-Zwirble W. T., Lidicker J. et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29(7):1303–10.

8. Moore L. J., Moore F. A. Early diagnosis and evidence-based care of surgical sepsis. J Intensive Care Med 2013;28(2):107–17.

9. Hartman M. E., Linde-Zwirble W. T. Angus D. C., Watson R. S. Trends in the epidemiology of pediatric severe sepsis. Pediatr Crit Care Med 2013;14(7):686–93.

10. Kumar A., Roberts D., Wood K. E. et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34(6):1589–96.

11. Kumar A., Ellis P., Arabi Y. et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009;136(5):1237–48.

12. Marshall J. C., Reinhart K.; International Sepsis Forum. Biomarkers of sepsis. Crit Care Med 2009;37(7):2290–8.

13. Pierrakos C, Vincent J. L. Sepsis biomarkers: a review. Crit Care 2010;14(1):R15.

14. Samraj R. S., Zingarelli B., Wong H. R. Role of biomarkers in sepsis care. Shock 2013;40(5):358–65.

15. Reinhart K., Meisner M. Biomarkers in the critically ill patient: procalcitonin. Crit Care Clin 2011;27(2):253–63.

16. Vincent J. L., Donadello K., Schmit X. Biomarkers in the critically ill patient: C-reactive protein. Crit Care Clin 2011;27(2):241–51.

17. Christ-Crain M., Muller B. Procalcitonin in bacterial infections – hype, hope, more or less? Swiss Med Wkly 2005; 135(31–32):451–60.

18. Вельков В. В. Прокальцитонин и С-реактивный белок в современной лабораторной диагностике. Часть 1. Клинико-лабораторный консилиум. 2008;6(25):46–52. [Velkov V. V. Procalcitonin and C-reactive protein in the state-of-art laboratory diagnostics. Part 1. Klinikolaboratornyi konsilium = Clinical and Laboratory Consultation. 2008;6(25):46–52. (In Russ.)].

19. Вельков В. В. Прокальцитонин и С-реактивный белок в современной лабораторной диагностике. Часть 2. Клинико-лабораторный консилиум. 2009;1(26):34–48. [Velkov V. V. Procalcitonin and C-reactive protein in the state-of-art laboratory diagnostics. Part 2. Klinikolaboratornyi konsilium = Clinical and Laboratory Consultation. 2009;1(26):34–48 (In Russ.)].

20. Ingram N. Procalcitonin: does it have a role in the diagnosis, management and prognosis of patients with sepsis? JICS 2013;14(3):226–30.

21. Biller K., Fae F., Germann R. et al. How reliable is procalcitonin as an inflammatory marker? Laboratoriums Medizin 2012;35(6):1–6.

22. Meisner M. Update on procalcitonin measurements. Ann Lab Med 2014;34(4):263–73.

23. Sridharan P., Chamberlain R. S. The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills? Surg Infect (Larchmt) 2013;14(6):489–511.

24. Yaegashi Y., Shirakawa K., Sato N. et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother 2005;11(5):234–8.

25. Endo S., Takahashi G., Shozushima T. et al. Usefulness of presepsin (soluble CD14 subtype) as a diagnostic marker for sepsis. JAAM 2012;23:27–38.

26. Вельков В. В. Пресепсин – новый высокоэффективный биомаркер сепсиса. Клинико-лабораторный консилиум. 2012;2(42):56–62. [Velkov V. V. Presepsin as a new highly efficient sepsis biomarker. Kliniko-laboratornyi konsilium = Clinical and laboratory consultation. 2012;2(42):56–62. (In Russ.)].

27. Agilli M., Sener I., Yesildal F. et al. A new marker for the diagnosis of sepsis: Presepsin. J Investig Biochem 2012;1(1):55–7.

28. Faix J. D. Presepsin – the new kid on the sepsis block. Clin Biochem 2014;47(7–8):503–4.

29. Pizzolato E., Ulla M., Galluzzo C. et al. Role of presepsin for the evaluation of sepsis in the emergency department. Clin Chem Lab Med 2014;52(10):1395–400.

30. Zou Q., Wen W., Zhang X. Presepsin as a novel sepsis biomarker. World J Emerg Med 2014;5(1):16–9.

31. Окамура И., Томэ Р. Пресепсин: новый биомаркер для прогнозирования и диагностики сепсиса. Лаборатория 2014;(1):9–10. [Okamura I., Tome R. Presepsin: a new biomarker for forecasting and diagnostics of sepsis. Laboratoriya = Laboratory 2014;(1):9–10. (In Russ.)].

32. Antal-Szalmaґs P. Evaluation of CD14 in host defense. Eur J Clin Invest 2000;30(2):167–79.

33. Bas S., Gauthier B. R., Spenato U. et al. CD14 is an acute phase protein. J Immunol 2004;172(7):4470–9.

34. Savedra R. Jr, Delude R. L., Ingalls R. R. et al. Mycobacterial lipoarabinomannan recognition requires a receptor that shares components of the endotoxin signaling system. J Immunol 1996;157(6):2549–54.

35. Sellati T. J., Bouis D. A., Kitchens R. L. et al. Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides activate monocytic cells via a CD14-dependent pathway distinct from that used by lipopolysaccharide. J Immunol 1998;160(11):5455–64.

36. Dziarski R., Tapping R. I., Tobias P. S. Binding of bacterial peptidoglycan to CD14. J Biol Chem 1998;273(15):8680–90.

37. Klein B. S. Role of cell surface molecules of Blastomyces dermatidis in the pathogenesis and immunobiology of blastomycosis. Semin Respir Infect 1997;12(3):198–205.

38. Hailman E., Lichenstein H. S., Wurfel M. M. et al. Lipopolysaccharide (LPS) binding protein accelerates the binding of LPS to CD14. J Exp Med 1994;179(1):269–76.

39. Fan X., Stelter F., Menzel R. Structures in Bacillus subtilis are recognized by CD14 ina lipopolysaccharide binding protein-dependent reaction. Infect Immun 1999;67(6):2964–8.

40. Hasebe A., Mu H. H., Washburn L. R. Inflammatory lipoproteins purified from a toxigenic and arthritogenic strain of Mycoplasma arthritidis are dependent on Toll-like receptor 2 and CD14. Infect Immun 2007;75(4):1820–6.

41. Grunwald U., Krüger C., Westermann J. et al. An enzyme-linked immunosorbent assay for the quantification of solubilized CD14

42. in biological fluids. J Immunol Methods 1992;155(2):225–32.

43. Shirakawa K., Naitou K., Hirose J. et al. The new sepsis marker, sCD14-ST, induction mechanism in the rabbit sepsis models. Crit Care 2010;14(Suppl 2):19.

44. Dandona P., Nix D., Wilson M. F. et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994;79(6):1605–8.

45. Endo S., Suzuki Y., Takahashi G. et al. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis:

46. A multicenter prospective study. J Infect Chemother 2013;18(6):891–7.

47. Fukui Y., Okamura Y. Clinical performance of a point-of-care assay for measurement of presepsin in patients with bacteremia. Crit Care 2013;17(Suppl 4):58.

48. Shozushima T., Takahashi G., Matsumoto N. et al. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011;17(6):764–9.

49. Liu B., Chen Y. X., Yin Q. et al. Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department. Crit Care 2013;17(5):R244.

50. Kojika M., Takahashi G., Matsumoto N. et al. Serum levels of soluble CD14 subtype reflect the APACHE II and SOFA scores. Med Postgrad 2010;48:46–50.

51. Spanuth E., Ebelt H., Ivandic B. et al. Diagnostic and prognostic value of presepsin (soluble CD14 subtype) in emergency patients with early sepsis using the new assay PATHFAST Presepsin. 21st International Congress of Clinical Chemistry and Laboratory Medicine, 2011. Poster 0333.

52. Spanuth E., Wilhelm J., Loppnow H. et al. Utility of PATHFAST Presepsin in Septic Patients Admitted to the Emergency Room. 1st Central and Eastern European Sepsis Forum SepsEast. Budapest, September 19–23, 2012.

53. Ulla M., Pizzolato E., Lucchiari M. et al. Diagnostic and prognostic value of Presepsin in the management of sepsis in the emergency department: a multicentre prospective study. Crit Care 2013;17(4):R168.

54. Romualdo L. G., Torrella P. E., González M. V. Diagnostic accuracy

55. of presepsin (soluble CD14 subtype) for prediction of bacteremia in patients with systemic inflammatory response syndrome in the Emergency Department. Clin Biochem 2014;47(7–8):505–8.

56. Cebreiros-Lopez I., Noguera-Velasco J. A., Martinez-Ruiz A. et al. Correlation of Presepsin (SCD14-ST) with PCT in critically ill patients: Diagnostics usefulness in Sepsis. Euro Med Lab 2013. Poster M097.

57. Chenevier-Gobeaux C., Trabattoni E., Roelens M. et al. Presepsin (sCD14-ST) in emergency department: the need for adapted threshold values? Clin Chim Acta 2014; 427:34–6.

58. Masson S., Caironi P., Spanuth E. et al. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care 2014;18(1):R6.

59. Shirakawa K. Diagnosis of respiratory tract infectious disease using urine specimens. European Patent Application EP 2 711 710 A1.

60. Sargentini V., Ceccarelli G., D,Alessandro M. et al. Presepsin as a potential marker for bacterial infection relapse in critical care patients. A preliminary study. Clin Chem Lab Med 2015;53(4):567–73.

61. Spanuth E., Giannitsis E. Diagnosis of sespis and monitoring of weaning from mechanical ventilation in critical ill patients by PATHFAST Presepsin. 20th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine. May 19–23, 2013. Milano, Italy. T022.

62. Vodnik T., Kaljevic G., Tadicet T. еt al. Presepsin (sCD14-ST) in preoperative diagnosis of abdominal sepsis. Clin Chem Lab Med 2013;51(10):2053–62.

63. Novelli G., Morabito V., Ferretti G. et al. Pathfast presepsin assay for early diagnosis of bacterial infections in surgical patients: preliminary study. Transplant Proc 2013;45(7):2750–3.

64. Демидова В. С., Ушакова Т. А., Звягин А. А. и др. Пресепсин в диагностике гнойных осложнений у хирургических больных и пациентов с ожоговой травмой при критических состояниях. Материалы XV сессии МНОАР 28 марта 2014 г.

65. С. 16–7. [Demidova V. S., Ushakova T. A., Zvyagin A. A. et al. Presepsin in diagnostics of purulent complications of surgical patients and patients with burn injuries in critical states. Materials of the XV Session of the Moscow Scientific Society of Anesthesiologists and Resuscitators, March 28, 2014. Pp. 16–7 (In Russ.)].

66. Попов Д. А., Плющ М. Г., Овсеенко С. Т. и др. Мониторинг уровня SCD14-ST (пресепсина) в предоперационном периоде

67. у кардиохирургических больных. Анестезиология и реаниматология 2013;3:30–5. [Popov D. A., Plyushch M. G., Ovseyenko S. T. et al. Monitoring of the level of SCD14-ST (Presepsin) during the pre-surgery period of cardiac surgery patients. Ansteziologiya

68. i reanimatologiya = Anesthesiology and Intensive Care 2013;3:30–5. (In Russ.)].

69. Свирко Ю. С., Кулагина И. В., Подоксенов Ю.К. и др. Использование пресепсина в диагностике системного воспалительного ответа в послеоперационном периоде

70. у кардиохирургических пациентов с ишемической болезнью сердца. Лаборатория 2014;2:56. [Svirko Yu. S., Kulagina I. V., Podoksenov Yu. K. et al. Application of presepsin in diagnostics of systemic inflammatory response during the inflammatory period of cardiac surgery patients with ischemic heart disease. Laboratoriya = Laboratory 2014;2:56. (In Russ.)].

71. Полякова И. Н., Андросова М. В., Мазанов М. Х., Годков М. А. Динамика уровня пресепсина в крови у больных с ишемической болезнью сердца, оперированных в условиях искусственного кровообращения. VII научно-практическая конференция «Современные технологии и методы диагностики различных групп заболеваний, лабораторный анализ». Тезисы. Москва, 14 мая 2014 г. [Polyakova I. N., Androsova M. V., Mazanov M.Kh., Godkov M. A. Dynamics of the presepsin level in blood of patients with ischemic heart disease after surgeries in conditions of artificial blood circulation. The VII Research and Practical Conference “State-of-Art Technologies and Methods of Diagnostics of Various Disease Groups, Laboratory Analysis”. Theses. Moscow, May 14, 2014. (In Russ.)].

72. Sponholz C., Sakr Y., Reinhart K., Brunkhorst F. Diagnostic value and prognostic implications of serum procalcitonin after cardiac surgery: a systematic review of the literature. Crit Care 2006;10(5):R145.

73. Aouifi A., Piriou V., Blanc P. et al. Effect of cardiopulmonary bypass on serum procalcitonin and C-reactive protein concentrations. Br J Anaesth 1999;83(4):602–7.

74. Cakır Madenci O., Yakupoğlu S., Benzonana N. et al. Evaluation of soluble CD14 subtype (presepsin) in burn sepsis. Burns 2013;40(4):664–9.

75. Beale R., Reinhart K., Brunkhorst F. M. et al. Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registry. Infection 2009,37(3):222–32.

76. Gando S., Iba T., Eguchi Y. et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006;34(3):625–31.

77. Ishikura H., Nishida T., Murai A. et al. New diagnostic strategy for sepsis-induced disseminated intravascular coagulation:

78. a prospective single-center observational study. Crit Care 2014;18(1):R19.

79. Urbonas V., Eidukaitė A., Tamulienė I. The predictive value of soluble biomarkers (CD14 subtype, interleukin-2 receptor, human leucocyte antigen-G) and procalcitonin in the detection of bacteremia and sepsis in pediatric oncology patients with chemotherapy-induced febrile neutropenia. Cytokine 2013;62(1):34–7.

80. Makarova P., Galstyan G., Krechetova A. et al. Usefulness of presepsin (PSP) for assessment of sepsis in leukopeniс patients (pts). Abstr. 27th Annual Congress, ESICM LIVES 2014, Barcelona, Spain, 27 September – 1 October 2014. Crit Care 2014.

81. Chiesa C., Natale F., Pascone R. et al. C reactive protein and procalcitonin: Reference intervals for preterm and term newborns during the early neonatal period. Clin Chim Acta 2011;412(11–12):1053–9.

82. Mussap M., Puxeddu E., Burrai P. et al. Soluble CD14 subtype (sCD14-ST) presepsin in critically ill preterm newborns: preliminary reference ranges. J Matern Fetal Neonatal Med 2012;25(Suppl 5):51–3.

83. Casani A., Cocca F., Coletta C. et al. Presepsin values in health mature and near term neonates using new immunoassay:

84. a preliminary study. Abstract. J Pediatr Neonat Individualized Med 2012;1(1):56.

85. Kwiatkowska-Gruca M., Behrendt J., Sonsala A. et al. Presepsyna (rozpuszczalny podtyp CD14-ST) jako diagnostyczny biomarker posocznicy u noworodków. Pediatria Polska 2013;88(5):392–7.

86. Abd Elaziz H. Diagnosis of neonatal using different sepsis markers. Abstract. 4th International Conference on Biomarkers and Clinical Research. July 15–17, 2013.

87. Puxeddu E., Noto A., Mussap M. et al. Is soluble CD14 subtype (sCD14-ST) presepsin and early biomarker of neonatal sepsis? Yes

88. it is. Neonat Individualized Med 2012;1(1):56.

89. Козлова Е. М., Шунькина Г. Л., Чумак Н.М. и др. Уровень пресепсина крови у новорожденных детей. Лаборатория 2014;2:31. [Kozlova E. M., Shun,kina G. L., Chumak N. M. et al. The level of presepsin fluid of newborn babies. Laboratoriya = Laboratory 2014;2:31. (In Russ.)].

90. Плющ М. Г., Рогальская Е. А., Самсонова Н.Н. и др. Информативность уровней пресепсина для стратификации риска у пациентов после операций на сердце и сосудах. Лаборатория 2014;2:49. [Plyushch M. G., Rogalskaya E. A., Samsonova N. N. et al. Informative nature of presepsin levels for stratification

91. of risks of patients after cardiovascular surgeries. Laboratoriya = Laboratory 2014;2:49. (In Russ.)].

92. Malíčková K., Koucký M., Pařízek A. et al. Diagnostic and prognostic value of presepsin in preterm deliveries. J Matern Fetal Neonatal Med 2014:1–26.

93. Tsuji S., Ohshima S., Yura A. et al. Serum presepsin (soluble CD14-subtypr) as a novel useful biomarker for infection in patients with rheumatoid arthritis (RA). Ann Rheum Dis 2013;72(Suppl3):314.

94. Novelli G., Morabito V., Ferretti G. et al. Diagnostic value of prespesin in сirthroic patients. J Hepatol 2013;58(Suppl 1):S95–6.

95. Okasha H., Elgohary A., Abd El Moety A. et al. Diagnostic and prognostic value of serum presepsin in cirrhotic patients with spontaneous bacterial peritonitis. Abstracts of 24th ECCMID Congress. Barcelona, May 10–13, 2014.

96. Смирнов Г. В., Красносельский М. Я., Фролков В. В. и др. Пресепсин – эффективный маркер гнойно-септических осложнений острого панкреатита. Эфферентная терапия 2014;20(1):30. [Smirnov G. V., Krasnoselskiy M. Ya., Frolkov V. V. et al. Presepsin as an efficient market of purulent and septic complications of acute pancreatitis. Efferentnaya terapiya = Efferent Therapy 2014;20(1):30. (In Russ.)].

97. Bagshaw S. M., George C., Bellomo R. Early acute kidney injury and sepsis: a multicentre evaluation. Crit Care 2008;12(2):R47.

98. Matejovic M., Chvojka J., Radej J. et al. Sepsis and acute kidney injury are bidirectional. Contrib Nephrol 2011;174:78–88.

99. Mehta R. L., Bouchard J., Soroko S. B. et al. Sepsis as a cause and consequence of acute kidney injury: Program to Improve Care in Acute Renal Disease. Intensive Care Med 2011;37(2):241–8.

100. Lai T. S., Wang C. Y., Pan S. C. et al. Risk of developing severe sepsis after acute kidney injury: a population-based cohort study. Crit Care 2013;17(5):R231.

101. Maravic-Stojkovic V., Lausevic-Vuk L., Jovic M. et al. Levels of рresepsin and midregion-proadrenomedullin in septic patients with end-stage renal disease after cardiovascular surgery: 1-year follow up study. J Clin Exp Cardiol 2014;5:5.

102. Nakamura Y., Ishikura H., Nishida T. et al. Usefulness of presepsin in the diagnosis of sepsis in acute kidney injury patients. Crit Care 2013;17(Suppl 2):36.

103. Nakamura Y., Ishikura H., Ichiki R. et al. Usefulness of presepsin and procalcitonin levels in the diagnosis of sepsis in patients with acute kidney injury. Crit Care 2014;18(Suppl 1):213.

104. Lu X. L., Xiao Z. H., Yang M. Y. et al. Diagnostic value of serum procalcitonin in patients with chronic renal insufficiency:

105. a systematic review and meta-analysis. Nephrol Dial Transplant 2013;28(1):122–9.

106. Amour J., Birenbaum A., Langeron O. et al. Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis

107. of postoperative infection after vascular surgery. Crit Care Med 2008;36:1147–54.

108. Hattori T., Nishiyama H., Kato H. et al. Clinical value of procalcitonin for patients with suspected bloodstream infection. Am J Clin Pathol 2014;141(1):43–51.

109. Яковлев А. Ю., Абрамов А. В., Серопян М.Ю. и др. Динамика лабораторных маркеров сепсиса при проведении селективной ЛПС-сорбции. Лаборатория 2014;2:69. [Yakovlev A. Yu., Abramov A. V., Seropyan M. Yu. et al. Dynamics of laboratory sepsis markers in the course of performance of selective LPS sorption. Laboratoriya = Laboratory 2014;2:69. (In Russ.)].

110. Яковлев А. Ю., Зайцев Р. М., Ниязматов А. А. и др. Динамика лабораторных маркеров сепсиса во время продленной вено-венозной гемофильтрации. Медицинский альманах 2013;3:148–9. [Yakovlev A. Yu., Zaitsev R. M., Niyazmatov A. A. et al. Dynamics of laboratory sepsis markers in the course of continuous venovenous hemofiltration. Meditsinskiy al,manah = Medical Almanac 2013;3:148–9. (In Russ.)].

111. Liu B., Yin Q., Chen Y. X. et al. Role of presepsin (sCD14-ST) and the CURB65 scoring system in predicting severity and outcome of community-acquired pneumonia in an emergency department. Respir Med 2014;108(8):1204–13.

112. Еремина Н. А., Ткаля Н. Г., Воронина Н.А. и др. Динамика пресепсина при антибактериальной терапии муковисцидоза на стадии обострения обструктивного слизисто-гнойного бронхита. Клинический случай. Лаборатория 2014;2:25. [Eryomina N. A., Tkalya N. G., Voronina N. A. et al. Presepsin dynamics in the antibacterial therapy of cystic fibrosis at the acute stage of obstructive mucopurulent bronchitis. Clinical case. Laboratoriya = Laboratory 2014;2:25. (In Russ.)].

113. Spanuth E., Hess G., Giannitsis E. et al. Comparison of sCD14-ST (рresepsin) with еight biomarkers for mortality prediction

114. in patients admitted with acute heart failure. 2014 AACC Annual Meeting Abstracts. B-331.

115. Spanuth E., Thomae R., Giannitsis E. Presepsin (sCD14-ST) in acute coronary syndromes and heart failure. 2014 AACC Annual Meeting Abstracts. B-343.

116. Sinning C. R., Sinning J. M., Schulz A. et al. Association of serum procalcitonin with cardiovascular prognosis in coronary artery disease. Circ J 2011;75(5): 118–91.

117. Kafkas N., Venetsanou K., Patsilinakos S. et al. Procalcitonin in acute myocardial infarction. Acute Card Care 2008; 10(1):30–6.

118. Picariello C., Lazzeri C., Chiostri M. et al. Procalcitonin in patients with acute coronary syndromes and cardiogenic shock submitted to percutaneous coronary intervention. Intern Emerg Med 2009;4(5):403–8.


Для цитирования:

Вельков В.В. ИСПОЛЬЗОВАНИЕ БИОМАРКЕРА ПРЕСЕПСИН ДЛЯ РАННЕЙ И ВЫСОКОСПЕЦИФИЧНОЙ ДИАГНОСТИКИ СЕПСИСА. Раны и раневые инфекции. Журнал имени проф. Б.М. Костючёнка. 2015;2(1):53-82.

For citation:

USE OF THE BIOMARKER PRESEPSIN FOR THE EARLY AND HIGHLY SPECIFIC DIAGNOSIS OF SEPSIS. Wounds and wound infections. The prof. B.M. Kostyuchenok journal. 2015;2(1):53-82. (In Russ.)

Просмотров: 627

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 2408-9613 (Print)
ISSN 2500-0594 (Online)